LT3077389T - Kristalinė (s)-(2-(6-chlor-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanono forma ir jos panaudojimas kaip oreksino receptoriaus antagonisto - Google Patents

Kristalinė (s)-(2-(6-chlor-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanono forma ir jos panaudojimas kaip oreksino receptoriaus antagonisto

Info

Publication number
LT3077389T
LT3077389T LTEP14824107.8T LT14824107T LT3077389T LT 3077389 T LT3077389 T LT 3077389T LT 14824107 T LT14824107 T LT 14824107T LT 3077389 T LT3077389 T LT 3077389T
Authority
LT
Lithuania
Prior art keywords
methylpyrrolidin
methanone
triazol
imidazol
benzo
Prior art date
Application number
LTEP14824107.8T
Other languages
English (en)
Lithuanian (lt)
Inventor
Christoph Boss
Christine Brotschi
Markus Gude
Bibia Heidmann
Thierry Sifferlen
Markus Von Raumer
Jodi T. Williams
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of LT3077389T publication Critical patent/LT3077389T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTEP14824107.8T 2013-12-03 2014-12-02 Kristalinė (s)-(2-(6-chlor-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanono forma ir jos panaudojimas kaip oreksino receptoriaus antagonisto LT3077389T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013060596 2013-12-03
PCT/IB2014/066508 WO2015083070A1 (en) 2013-12-03 2014-12-02 Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
LT3077389T true LT3077389T (lt) 2017-12-11

Family

ID=52282786

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14824107.8T LT3077389T (lt) 2013-12-03 2014-12-02 Kristalinė (s)-(2-(6-chlor-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanono forma ir jos panaudojimas kaip oreksino receptoriaus antagonisto

Country Status (30)

Country Link
US (1) US9914720B2 (cg-RX-API-DMAC7.html)
EP (1) EP3077389B1 (cg-RX-API-DMAC7.html)
JP (1) JP6496733B2 (cg-RX-API-DMAC7.html)
KR (1) KR102361418B1 (cg-RX-API-DMAC7.html)
CN (1) CN105793257B (cg-RX-API-DMAC7.html)
AU (1) AU2014358742B2 (cg-RX-API-DMAC7.html)
CA (1) CA2929423C (cg-RX-API-DMAC7.html)
CL (1) CL2016001342A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119695T1 (cg-RX-API-DMAC7.html)
DK (1) DK3077389T3 (cg-RX-API-DMAC7.html)
EA (1) EA030137B1 (cg-RX-API-DMAC7.html)
ES (1) ES2651475T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171773T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035731T2 (cg-RX-API-DMAC7.html)
IL (1) IL245923B (cg-RX-API-DMAC7.html)
LT (1) LT3077389T (cg-RX-API-DMAC7.html)
MA (1) MA39163B1 (cg-RX-API-DMAC7.html)
MX (1) MX364208B (cg-RX-API-DMAC7.html)
MY (1) MY179862A (cg-RX-API-DMAC7.html)
NO (1) NO3077389T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ721438A (cg-RX-API-DMAC7.html)
PH (1) PH12016500988A1 (cg-RX-API-DMAC7.html)
PL (1) PL3077389T3 (cg-RX-API-DMAC7.html)
PT (1) PT3077389T (cg-RX-API-DMAC7.html)
SA (1) SA516371231B1 (cg-RX-API-DMAC7.html)
SI (1) SI3077389T1 (cg-RX-API-DMAC7.html)
TW (1) TWI664177B (cg-RX-API-DMAC7.html)
UA (1) UA119549C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015083070A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201604499B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
ES2696708T3 (es) 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Uso de derivados de bencimidazol-prolina
SI3619199T1 (sl) * 2017-05-03 2021-11-30 Idorsia Pharmaceuticals Ltd Priprava derivatov 2-((1,2,3)triazol-2-il)-benzojske kisline
PH12022552763A1 (en) 2020-04-19 2024-03-25 Idorsia Pharmaceuticals Ltd Medical use of daridorexant
KR20230142554A (ko) * 2021-02-02 2023-10-11 메드샤인 디스커버리 아이엔씨. 테트라하이드로피롤로사이클릭 화합물 및 이의 용도
WO2023160004A1 (zh) * 2022-02-25 2023-08-31 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
ES3038762A1 (es) 2024-04-12 2025-10-14 Moehs Iberica Sl Procedimiento de síntesis de ácido 5-metoxi-2-(2H-1,2,3-triazol-2yl)benzoico, sal sódica de dicho ácido como intermedio de síntesis y uso del ácido o de su sal en la preparación de daridorexant y ciertos intermedios en la síntesis del mismo

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
AU2001272476A1 (en) 2000-06-16 2001-12-24 Smithkline Beecham Plc Piperidines for use as orexin receptor antagonists
CA2425185A1 (en) 2000-10-06 2002-04-11 Stephane De Lombaert Benzimidazole and indole derivatives as crf receptor modulators
DE60108420T2 (de) 2000-11-28 2005-12-22 Smithkline Beecham P.L.C., Brentford Morpholinderivate als antagonisten an orexinrezeptoren
MXPA03010129A (es) 2001-05-05 2004-03-10 Smithkline Beecham Plc N-aroilaminas-ciclicas.
JP2004534026A (ja) 2001-05-05 2004-11-11 スミスクライン ビーチャム パブリック リミテッド カンパニー オレキシン受容体アンタゴニストとしてのn−アロイルサイクリックアミン誘導体
IL159041A0 (en) * 2001-06-28 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
WO2004026866A1 (en) 2002-09-18 2004-04-01 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
HRP20150371T1 (hr) 2004-03-01 2015-05-08 Actelion Pharmaceuticals Ltd. Supstituirani derivati 1,2,3,4-tetrahidroizokinolina
JP4582722B2 (ja) 2006-03-15 2010-11-17 アクテリオン ファーマシューティカルズ リミテッド 記憶機能を向上させるテトラヒドロイソキノリン誘導体
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
DE602007012910D1 (de) 2006-08-15 2011-04-14 Actelion Pharmaceuticals Ltd Azetidinverbindungen als orexin-rezeptor-antagonisten
ES2350460T3 (es) 2006-09-29 2011-01-24 Actelion Pharmaceuticals Ltd. Derivados de 3-aza-biciclo[3.1.0]hexano.
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
ATE483707T1 (de) 2007-05-14 2010-10-15 Actelion Pharmaceuticals Ltd 2-cyclopropylthiazolderivate
CA2687230A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
PE20090441A1 (es) 2007-07-03 2009-05-08 Glaxo Group Ltd DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA
BRPI0813218A2 (pt) 2007-07-03 2014-12-23 Actelion Pharmaceuticals Ltd Composto, composição farmacêutica que o contém como princípio ativo e uso do composto.
KR20100046047A (ko) 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
JP2010534646A (ja) 2007-07-27 2010-11-11 アクテリオン ファーマシューティカルズ リミテッド トランス−3−アザ−ビシクロ[3.1.0]ヘキサン誘導体
WO2009040730A2 (en) 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
EP2247586B1 (en) 2008-02-21 2012-04-25 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
CN102083827A (zh) 2008-07-07 2011-06-01 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的噻唑烷化合物
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
WO2010060470A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
EP2358713A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
EP2358712A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
MX2011005800A (es) 2008-12-02 2011-06-20 Glaxo Group Ltd Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos.
KR20110091581A (ko) 2008-12-02 2011-08-11 글락소 그룹 리미티드 N-{[1r,4s,6r-3-(2-피리디닐카르보닐)-3-아자비시클로[4.1.0]헵트-4-일]메틸}-2-헤테로아릴아민 유도체 및 그의 용도
GB0823467D0 (en) * 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
EA201171293A1 (ru) 2009-04-24 2012-05-30 Глэксо Груп Лимитед 3-азабицикло[4.1.0]гептаны, применяемые в качестве антагонистов орексина
JP5744203B2 (ja) 2010-08-24 2015-07-08 アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体
CN103201261A (zh) 2010-11-10 2013-07-10 埃科特莱茵药品有限公司 用作为食欲素受体拮抗剂的内酰胺衍生物
US9303023B2 (en) 2011-02-18 2016-04-05 Actelion Pharmaceuticals Ltd. Pyrazole and imidazole derivatives useful as orexin antagonists
MX343837B (es) 2011-11-08 2016-11-24 Actelion Pharmaceuticals Ltd Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
SG11201502493XA (en) 2012-10-10 2015-04-29 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
ES2696708T3 (es) 2013-12-04 2019-01-17 Idorsia Pharmaceuticals Ltd Uso de derivados de bencimidazol-prolina

Also Published As

Publication number Publication date
AU2014358742A1 (en) 2016-07-07
CA2929423A1 (en) 2015-06-11
CA2929423C (en) 2021-12-07
PH12016500988B1 (en) 2016-06-20
CY1119695T1 (el) 2018-04-04
JP6496733B2 (ja) 2019-04-03
PH12016500988A1 (en) 2016-06-20
CN105793257A (zh) 2016-07-20
MX364208B (es) 2019-04-16
EP3077389A1 (en) 2016-10-12
IL245923A0 (en) 2016-08-02
AU2014358742B2 (en) 2019-02-07
TW201605838A (zh) 2016-02-16
DK3077389T3 (da) 2017-11-13
BR112016012628A8 (pt) 2017-12-26
JP2016539136A (ja) 2016-12-15
EA201600435A1 (ru) 2016-11-30
HRP20171773T1 (hr) 2017-12-29
HK1225731B (en) 2017-09-15
KR20160092015A (ko) 2016-08-03
CL2016001342A1 (es) 2016-11-18
UA119549C2 (uk) 2019-07-10
ES2651475T3 (es) 2018-01-26
MA39163B1 (fr) 2018-09-28
KR102361418B1 (ko) 2022-02-09
EA030137B1 (ru) 2018-06-29
EP3077389B1 (en) 2017-09-13
HUE035731T2 (hu) 2018-05-28
US9914720B2 (en) 2018-03-13
TWI664177B (zh) 2019-07-01
WO2015083070A1 (en) 2015-06-11
MX2016007215A (es) 2016-09-07
ZA201604499B (en) 2019-04-24
SA516371231B1 (ar) 2018-02-20
SI3077389T1 (en) 2018-01-31
NZ721438A (en) 2021-12-24
IL245923B (en) 2019-09-26
CN105793257B (zh) 2018-11-13
BR112016012628A2 (cg-RX-API-DMAC7.html) 2017-08-22
MY179862A (en) 2020-11-18
PT3077389T (pt) 2017-12-15
US20160368901A1 (en) 2016-12-22
MA39163A1 (fr) 2017-11-30
PL3077389T3 (pl) 2018-03-30
NO3077389T3 (cg-RX-API-DMAC7.html) 2018-02-10

Similar Documents

Publication Publication Date Title
ZA201604499B (en) Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
ZA201604501B (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
EP2925321A4 (en) 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
EP2964226A4 (en) 2-pyridyloxy-4-ESTER-orexin receptor antagonists
EP2945630A4 (en) 4-FLUORPIPERIDINOREXIN receptor antagonists
HRP20181429T1 (hr) Novi derivati benzimidazola kao inhibitori kinaze
ZA201404189B (en) 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
LT3483163T (lt) Triazol[4,5-d]pirimidino dariniai kaip cb2 receptorių antagonistai
SMT201700141T1 (it) Composti di 1,3-ossazolidina o 1,3-ossazinano come antagonisti dei recettori dell'orexina
SMT201600012B (it) Composti eterociclici come leganti del recettore h3 dell'istamina
GB201321089D0 (en) Leukotriene receptor antagonists and their derivatives for use as antibacterial agents
TH1601000390A (th) เกลือของอนุพันธ์ 2-อะมิโน-1-ไฮดรอกซีเอทริล-8-ไฮดรอกซีควิโนลิน-2-(1H)-โอน(2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one) ซึ่งมีทั้งฤทธิ์มัสคารินิก รีเซพเตอร์แอนทาโกนิสและฤทธิ์ (เบต้า)2 อะดรีเนอร์จิกรีเซพเตอร์อะโกนิสต์